BRISTOL-MYERS SQUIBB COMPANY Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $85.00 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-10-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2025-10-30
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-09-30 was $85.00M.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2025-06-30 was $300.00M.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2014-09-30 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for the quarter ending 2012-12-31 was $0.00.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2012 was $1.83B, a 6435.71% increase from fiscal 2011.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2011 was $28.00M, a 180.00% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2010 was $10.00M.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 3 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 6 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 9 month | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|---|---|---|
| 2025-09-30 | $85.00M 10-Q · filed 2025-10-30 | $385.00M derived: sum of 2 quarters · filed 2025-10-30 | $385.00M 10-Q · filed 2025-10-30 | |
| 2025-06-30 | $300.00M 10-Q · filed 2025-07-31 | |||
| 2014-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-24 | $310.00M 10-Q · filed 2014-10-24 | ||
| 2014-06-30 | $310.00M 10-Q · filed 2015-07-23 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $1.83B derived: sum of 2 quarters · filed 2015-02-13 | $1.83B 10-K · filed 2015-02-13 | |
| 2012-09-30 | $1.83B 10-Q · filed 2013-10-23 | $1.83B 10-Q · filed 2013-10-23 | ||
| 2011-12-31 | $28.00M 10-K · filed 2012-02-17 | |||
| 2011-09-30 | $13.00M 10-K · filed 2012-02-17 | |||
| 2011-03-31 | $15.00M 10-K · filed 2012-02-17 | $25.00M derived: sum of 2 quarters · filed 2012-02-17 | ||
| 2010-12-31 | $10.00M 10-K · filed 2012-02-17 | $10.00M 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |